From May 12 to 16, 2025, MOLCURE will be participating in the 21st Annual PEGS Boston. On May 13 at 12:30 PM, our CEO/CSO, Dr. Tamaki, will deliver a presentation in the “ML and Digital Integration in Biotherapeutic Analytics” track.

In his talk, titled “De Novo Antibody Discovery and Lead Optimization Utilizing Large Language Models”, Dr. Tamaki will introduce MOLCURE’s latest advancements in de novo antibody discovery and lead optimization, achieved through our AI drug discovery platform which integrates our proprietary antibody-specific large-language model with wet-lab experiments.

We warmly invite attendees to join Dr. Tamaki’s session.